Detail of the clinical trial
| Title of the trial | A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)P/142/2020 |
|---|---|
| EudraCT number | 2015-005010-30 |
| Protocol number | KTE-C19-104 |
| Sponsor | Kite Pharma, Inc., 2225 Colorado Avenue. Santa Monica, California 90404, United States of America |
| Indications | Hemato-oncology |
| Diagnosis | Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| Population in clinical trial |
Children (2-11 years) Adolescents (12-17 years) Adults (18-65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2021 |
| Date of approval by Institute (SÚKL) | 12. 11. 2021 |
| Date of approval by EC | |
| Date of initiation CT in ČR | |
| Date of ending CT in ČR | |
| Notice | |
| Sites | Fakultní nemocnice Brno, Klinika dětské onkologie, Jihlavská 20,Brno,625 00 |
cz